Last reviewed · How we verify
Predema (pamabrom)
Predema (generic name: pamabrom) is a pamabrom drug. It is currently FDA-approved.
Pamabrom is a small molecule active diuretic ingredient found in over-the-counter medications. It is a product that contains 8-bromotheophylline and aminoisobutanol.
At a glance
| Generic name | pamabrom |
|---|---|
| Drug class | pamabrom |
| Target | Adenosine receptor A1 |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Predema CI brief — competitive landscape report
- Predema updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Predema
What is Predema?
Predema (pamabrom) is a pamabrom drug.
What is the generic name of Predema?
pamabrom is the generic (nonproprietary) name of Predema.
What drug class is Predema in?
Predema belongs to the pamabrom class. See all pamabrom drugs at /class/pamabrom.
What development phase is Predema in?
Predema is FDA-approved (marketed).
What does Predema target?
Predema targets Adenosine receptor A1 and is a pamabrom.
Related
- Drug class: All pamabrom drugs
- Target: All drugs targeting Adenosine receptor A1
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Nephrology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing